QCOM
59
-4
CSX
68
3
ADI
49
-2
LRCX
49
-3
NUE
62
-2
AVGO
37
-7
PEG
62
4
URBN
67
5
ADBE
49
3
LNC
50
5
STX
55
-5
WFC
82
7
GME
71
6
PYPL
62
10
STT
67
3
ES
24
-4
LOW
58
2
NTRS
59
2
JBHT
70
2
AKAM
47
5
QCOM
59
-4
CSX
68
3
ADI
49
-2
LRCX
49
-3
NUE
62
-2
AVGO
37
-7
PEG
62
4
URBN
67
5
ADBE
49
3
LNC
50
5
STX
55
-5
WFC
82
7
GME
71
6
PYPL
62
10
STT
67
3
ES
24
-4
LOW
58
2
NTRS
59
2
JBHT
70
2
AKAM
47
5
Financhill
Back

Kymera Therapeutics 10K Form

Buy
78

KYMR
Kymera Therapeutics

Last Price:
50.04
Seasonality Move:
52.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $78.59M
Cash Flow: $-50M
Price / Cash Flow: 0
Annual Sales: $13.79
Price / Book: 3.76

Profitability

EPS (TTM): -2.34000
Net Income (TTM): $-167.47M
Gross Margin: --
Return on Equity: -27.19%
Return on Assets: -21.71%

Kymera Therapeutics Earnings Forecast

Key Kymera Therapeutics Financial Ratios

  • The Research & Development expenses have been 240.59% of Revenue.
  • The Interest Expense is -0.13% of Operating Income.
  • The Net Earning history of KYMR is -186.99% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Kymera Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.55
Quick Ratio: 8.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Buy
78
Kymera Therapeutics (KYMR) is a Buy

Is Kymera Therapeutics a Buy or a Sell?